Alcohol dose in septal ablation for hypertrophic obstructive cardiomyopathy

• DOI: 10.1016/j.ijcard.2021.02.056
• Publication Date: 2021-02-27T09:25:36Z
• Authors: Josef Veselka; Lothar Faber; Max Liebregts; Robert Cooper; Jaroslav Januska; Maksim Kashtanov; Maciej Dabrowski; Peter Riis Hansen; Hubert Seggewiss; Jiri Bonaventura; Eva Polakova; Eva Hansvenclova; Henning Bundgaard; Jurriën ten Berg; Rodney Hilton Sta...; Jiri Jarkovsky; Morten Kvistholm ...
• Keywords: Alcohol septal ablation; Heart septum

BackgroundThe aim of this study was to evaluate short- and long-term outcomes related dose alcohol administered during septal ablation (ASA) in patients with hypertrophic obstructive cardiomyopathy (HOCM). Current guidelines recommend using 1–3 mL the target perforator artery, but recommendation is based more on practical experience interventionalists rather than systematic evidence.MethodsWe included 1448 used propensity score match who received a low-dose (1.0–1.9 mL) versus high-dose (2.0–3.8 ASA.ResultsThe matched cohort analysis comprised 770 (n = 385 both groups). There similar occurrence 30-day post-procedural adverse events (13% vs. 12%; p 0.59), all-cause mortality rates (0.8% 0.5%; 1) group group, respectively. In follow-up (5.4 ± 4.5 years), total 110 (14%) died representing 2.58 deaths 2.64 per 100 patient-years low high (logrank, 0.92), were no significant differences dyspnea left ventricular outflow gradient between two groups. Patients treated underwent subsequent reduction procedures 0.04).ConclusionsMatched HOCM undergoing ASA or had outcomes. A higher rate repeated observed alcohol.